Fundamental Analysis of ADC THERAPEUTICS SA(NYSE:ADCT) stock

Fundamental Rating

Taking everything into account, ADCT scores 2 out of 10 in our fundamental rating. ADCT was compared to 568 industry peers in the Biotechnology industry. Both the profitability and financial health of ADCT have multiple concerns. ADCT is quite expensive at the moment. It does show a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

ADCT had negative earnings in the past year.

ADCT had a negative operating cash flow in the past year.

ADCT had negative earnings in each of the past 5 years.

In the past 5 years ADCT always reported negative operating cash flow.

1.2 Ratios

With a Return On Assets value of -105.18%, ADCT is not doing good in the industry: 77.35% of the companies in the same industry are doing better.

		Industry Rank	Sector Rank
ROA	-105.18%
ROE	N/A
ROIC	N/A

ROA(3y)-44.77%

ROA(5y)-53.37%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Gross Margin of ADCT (94.24%) is better than 95.22% of its industry peers.

The Profit Margin and Operating Margin are not available for ADCT so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	94.24%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

ADCT does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, ADCT has more shares outstanding

The number of shares outstanding for ADCT has been increased compared to 5 years ago.

Compared to 1 year ago, ADCT has a worse debt to assets ratio.

2.2 Solvency

Based on the Altman-Z score of -6.86, we must say that ADCT is in the distress zone and has some risk of bankruptcy.

ADCT's Altman-Z score of -6.86 is on the low side compared to the rest of the industry. ADCT is outperformed by 67.61% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF	N/A
Altman-Z	-6.86

ROIC/WACCN/A

WACC6.32%

2.3 Liquidity

ADCT has a Current Ratio of 4.92. This indicates that ADCT is financially healthy and has no problem in meeting its short term obligations.

ADCT has a Current ratio (4.92) which is in line with its industry peers.

A Quick Ratio of 4.68 indicates that ADCT has no problem at all paying its short term obligations.

ADCT has a Quick ratio (4.68) which is in line with its industry peers.

		Industry Rank	Sector Rank
Current Ratio	4.92
Quick Ratio	4.68

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The earnings per share for ADCT have decreased by -8.64% in the last year.

Looking at the last year, ADCT shows a small growth in Revenue. The Revenue has grown by 0.75% in the last year.

The Revenue has been growing by 129.19% on average over the past years. This is a very strong growth!

EPS 1Y (TTM)-8.64%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%27.59%

Revenue 1Y (TTM)0.75%

Revenue growth 3YN/A

Revenue growth 5Y129.19%

Sales Q2Q%27.4%

3.2 Future

Based on estimates for the next years, ADCT will show a quite strong growth in Earnings Per Share. The EPS will grow by 16.92% on average per year.

ADCT is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 30.34% yearly.

EPS Next Y40.7%

EPS Next 2Y21.59%

EPS Next 3Y16.92%

EPS Next 5YN/A

Revenue Next Year6.28%

Revenue Next 2Y8.97%

Revenue Next 3Y18.12%

Revenue Next 5Y30.34%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

ADCT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year ADCT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

ADCT's earnings are expected to grow with 16.92% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y21.59%

EPS Next 3Y16.92%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for ADCT!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

ADC THERAPEUTICS SA

NYSE:ADCT (12/18/2024, 4:15:00 PM)

After market: 1.92 +0.01 (+0.52%)

1.91

-0.22 (-10.33%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap184.68M

Analysts

Price Target

Short Float %

Short Ratio

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-105.18%
ROE	N/A
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	94.24%
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.35

Health

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	4.92
Quick Ratio	4.68
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

High Growth Momentum

Growth

EPS 1Y (TTM)-8.64%

EPS 3YN/A

EPS 5Y

EPS Q2Q%

EPS Next Y40.7%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)0.75%

Revenue growth 3YN/A

Revenue growth 5Y

Sales Q2Q%

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

ADC THERAPEUTICS SA (ADCT)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens